My NCBISign In

Display Settings:

Format

Send to:

Choose Destination

    J Cell Biol. 2004 Nov 8;167(3):399-403.

    Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis.

    Manning BD.

    Department of Genetics and Complex Diseases, Harvard School of Public Health, Boston, MA 02115, USA. bmanning@hsph.harvard.edu

    Erratum in:

    • J Cell Biol. 2004 Dec 20;167(6):1255.

    Proper regulation of the phosphoinositide 3-kinase-Akt pathway is critical for the prevention of both insulin resistance and tumorigenesis. Many recent studies have characterized a negative feedback loop in which components of one downstream branch of this pathway, composed of the mammalian target of rapamycin and ribosomal S6 kinase, block further activation of the pathway through inhibition of insulin receptor substrate function. These findings form a novel basis for improved understanding of the pathophysiology of metabolic diseases (e.g., diabetes and obesity), tumor syndromes (e.g., tuberous sclerosis complex and Peutz-Jegher's syndrome), and human cancers.

    PMID: 15533996 [PubMed - indexed for MEDLINE]

    PMCID: PMC2172491

    Supplemental Content

    Click here to read Click here to read
    Write to the Help Desk